Senseonics Holdings

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Senseonics achieves FDA milestone with Eversense 365, focuses on growth

Senseonics had a pivotal quarter with FDA approval of Eversense 365, driving positive feedback and strong adoption.
Financially, the company reported Q3 net revenue of $4.3 million with a gross loss of $4.1 million, focusing on cost reduction.
Efforts to reduce operating expenses and extend cash runway aim to address financial challenges and enhance stability.
With opportunities to accelerate sales, improve diabetes management, and expand market reach, Senseonics is poised for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

The company presented data on its continuous glucose monitoring system, but investors may be more excited about being joined by George Soros.

Here's Why Senseonics Jumped Higher Today

Investors reacted enthusiastically to a positive coverage decision for the company's Eversense CGM device.

Why Senseonics Holdings Shares Jumped Today

It wasn’t a good quarter for the diabetes-device company.

Here’s Why Shares of Senseonics Got Hammered Today

The continuous glucose monitoring systems maker's main problem: declining sales.

What's Behind Senseonics' Dismal Q3 Results?

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q3 2019 Results - Earnings Call Transcript

Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Senseonics Holdings (SENS) Q3 Earnings Expected to Decline

Geron

New Age Beverages

ViewRay

Written by: Craig Adeyanju | FinScreener Penny stocks, on the surface, look attractive because they generally have prices under $5. However, many penny stocks belong in that category for a reason and one of them is that they typically lack the trading volume required for them to be attractive to traders.

4 Best High Volume Penny Stocks To Consider

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q2 2019 Results - Earnings Call Transcript

Dilution is on the way, causing at least temporary pain for shareholders.

Why Senseonics Holdings Stock Sank Today

The continuous glucose system (CGM) maker posted solid revenue growth but missed Wall Street's revenue and earnings estimates.

What You Need to Know About Senseonics Holdings' Q1 Earnings Update

Senseonics Holdings Inc. (SENS) CEO Tim Goodnow on Q1 2019 Results - Earnings Call Transcript

Senseonics (SENS) delivered earnings and revenue surprises of -41.67% and -15.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q1 Loss, Lags Revenue Estimates

The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.

Senseonics Unveils Eversense Bridge Program in the U.S.

Investors need to pay close attention to Senseonics Holdings stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Senseonics Holdings Stock?

News for Senseonics Holdings Stock (SENS)